The biomarker related methods currently in use for diagnosis of AD are analysis of certain pathogenic proteins, including Ab and tau in cerebrospinal fluid (CSF), along with imaging techniques to identify brain atrophy, measure brain metabolism, and identify accumulation of pathogenic proteins in the brain [16]. This evidence concerns the gene MAPT and Alzheimer disease.